Last update 08 May 2025

Innovent Biomedical Technology (Hangzhou) Co., Ltd.

Private Company|2024|Zhejiang Sheng, China

Overview

Tags

Neoplasms
Respiratory Diseases
Digestive System Disorders
Monoclonal antibody
Dual payload Antibody drug conjugate (Dual payload ADC)
Biosimilar

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Top 5 Drug TypeCount
Dual payload Antibody drug conjugate (Dual payload ADC)1
Biosimilar1
Monoclonal antibody1
Top 5 TargetCount
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4)1
CEACAM5(Carcinoembryonic antigen related cell adhesion molecule 5)1

Related

2
Drugs associated with Innovent Biomedical Technology (Hangzhou) Co., Ltd.
IBI3020
Target
CEACAM5
Mechanism
CEACAM5 modulators
Active Org.
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
Originator Org.
Innovent Biomedical Technology (Hangzhou) Co., Ltd.
Active Indication
Solid tumor [+3]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Ipilimumab biosimilar (Innovent Biologics)
Target
CTLA4
Mechanism
CTLA4 inhibitors
Active Org.
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (Suzhou) Co. Ltd. [+2]
Originator Org.
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (Suzhou) Co. Ltd.
Active Indication
Mismatch repair-deficient Colonic Cancer [+5]
Inactive Indication
Acral Lentiginous Malignant Melanoma [+7]
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Innovent Biomedical Technology (Hangzhou) Co., Ltd.
NCT06945107
/ Not yet recruitingPhase 3
A Phase III, Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Switching to Picankibart in Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
NCT06946446
/ Not yet recruitingPhase 1
A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with Innovent Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Innovent Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data
100 Deals associated with Innovent Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Innovent Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
1
NDA/BLA
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Ipilimumab biosimilar (Innovent Biologics)
 ( CTLA4 )		Mismatch repair-deficient Colonic Cancer
More
NDA/BLA
IBI3020
 ( CEACAM5 )		Solid tumor
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free